Obatoclax
Small molecule targets BCL2, BCL2A1, BCL2L1, BCL2L10, BCL2L2-PABPN1, MCL1 via inhibition
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT00933985 | Jun 2009 → Apr 2013 | Burkitt lymphoma, Hodgkins lymphoma, acute undifferentiated leukemia, anaplastic large cell lymphoma +15 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00612612 | Jan 2008 → Jul 2013 | B-cell chronic lymphocytic leukemia, prolymphocytic leukemia | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00538187 | Dec 2007 → Apr 2011 | chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00438178 | Oct 2005 → Oct 2007 | hematopoietic and lymphoid cell neoplasm | Gemin X | Completed | No outcome recorded |
| Phase 1 | NCT00600964 | Sep 2004 → Jan 2006 | B-cell chronic lymphocytic leukemia | Gemin X | Completed | No outcome recorded |
| Phase 1/27 trials · 2 missed | ||||||
| Phase 1/2 | NCT01238146 | Oct 2010 → Apr 2012 | MALT lymphoma, mantle cell lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00719901 | Jul 2008 → Apr 2011 | plasma cell myeloma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00724841 | Jun → Jul 2008 | metastatic melanoma | Gemin X | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT00682981 | May 2008 → Nov 2011 | small cell lung carcinoma | Gemin X | Completed | Missed primary |
| Phase 1/2 | NCT00521144 | Aug 2007 → Aug 2010 | small cell lung carcinoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 1/2 | NCT00405951 | Oct 2006 → Nov 2008 | lung cancer | Gemin X | Completed | No outcome recorded |
| Phase 1/2 | NCT00407303 | Oct 2006 → Mar 2009 | mantle cell lymphoma | Gemin X | Completed | No outcome recorded |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT00918931 | Jun 2009 → Oct 2010 | leukemia, systemic mastocytosis | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00684918 | Apr 2008 → Aug 2009 | acute myeloid leukemia | Gemin X | Completed | Missed primary |
| Phase 2 | NCT00427856 | Mar 2007 → Feb 2009 | follicular lymphoma | Gemin X | Completed | No outcome recorded |
| Phase 2 | NCT00413114 | Dec 2006 → Feb 2009 | myelodysplastic syndrome | Gemin X | Completed | No outcome recorded |
| Phase 2 | NCT00360035 | Jul 2006 → Mar 2008 | myelofibrosis | Gemin X | Completed | No outcome recorded |
| Phase 2 | NCT00359892 | Jul 2006 → Sep 2007 | Hodgkins lymphoma | Gemin X | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01563601 | Aug 2012 → May 2016 | small cell lung carcinoma | Cephalon | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | obatoclax | “Obatoclax was administered to patients with advanced CLL at doses ranging from 3.5 to 14 mg/m(2) as a 1-hour infusion and from 20 to 40 mg/m(2) as a 3-hour infusion every 3 weeks.” PMID 18931344 ↗ Oct 2008 |
| Known as | GX15-070 | “Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.” PMID 18931344 ↗ Oct 2008 |
| Known as | GX15-070MS | “Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel” NCT00405951 ↗4“Obatoclax mesylate (GX15-070MS)” NCT00438178 ↗ “Obatoclax mesylate (GX15-070MS)” NCT00359892 ↗ “Obatoclax mesylate (GX15-070MS)” NCT00360035 ↗ “Obatoclax mesylate (GX15-070MS)” NCT00413114 ↗ |
| Known as | Obatoclax mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL408194 ↗ |
| Known as | Obatoclax Mesylate | “A Multicenter, Open-Label, 2-Stage, Phase II Study of Single-Agent Obatoclax Mesylate Administered For Three Consecutive Days Every 2 Weeks to Older Patients With Previously...” NCT00684918 ↗13“A Phase 1 Study of Obatoclax Mesylate (GX15-070MS) in Combination With Fludarabine-Based Chemoimmunotherapy in Previously Treated Patients With B-Cell Chronic Lymphocytic...” NCT00612612 ↗ “Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.” PMID 18931344 ↗ Oct 2008 “BACKGROUND: Obatoclax mesylate is a small-molecule Bcl-2 homology domain-3 mimetic that neutralizes antiapoptotic Bcl-2-related proteins.” PMID 25052051 ↗ Jun 2014 “Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of GMX1778.” NCT00724841 ↗ “Patients receive obatoclax mesylate IV over 3 hours and bortezomib IV on days 1, 4, 8, and 11.” NCT00719901 ↗ “obatoclax (obatoclax mesylate) administered as a single agent” NCT00933985 ↗ “obatoclax mesylate, a small-molecule Bcl-2 inhibitor” PMID 24997137 ↗ May 2014 “obatoclax mesylate, a Bcl-2 antagonist” PMID 21620511 ↗ May 2011 “Obatoclax mesylate (GX15-070MS)” NCT00359892 ↗ “Obatoclax mesylate (GX15-070MS)” NCT00360035 ↗ |
| Known as | Obatoclax: CEP-41601 | “Obatoclax: CEP-41601” NCT01563601 ↗ |
| Action | Inhibit | “Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins” NCT00359892 ↗5“Induced myeloid leukemia cell differentiation protein Mcl-1 inhibitor” CHEMBL408194 ↗ “Apoptosis regulator Bcl-X inhibitor” CHEMBL408194 ↗ “Apoptosis regulator Bcl-W inhibitor” CHEMBL408194 ↗ “Bcl-2-related protein A1 inhibitor” CHEMBL408194 ↗ “Bcl-2-like protein 10 inhibitor” CHEMBL408194 ↗ |
| Modality | Small molecule | “a small molecule pan-Bcl-2 family antagonist” PMID 22383790 ↗ Mar 2012 |
| Route | Intravenous | “administered as a 24-hour infusion every 2 weeks” NCT00360035 ↗ |
| Target | BCL2 | “through inhibition of the Bcl-2 family of proteins” NCT00360035 ↗ |
| Target | BCL2A1 | “Bcl-2-related protein A1 inhibitor” CHEMBL408194 ↗ |
| Target | BCL2L1 | “Apoptosis regulator Bcl-X inhibitor” CHEMBL408194 ↗ |
| Target | BCL2L10 | “Bcl-2-like protein 10 inhibitor” CHEMBL408194 ↗ |
| Target | BCL2L2-PABPN1 | “Apoptosis regulator Bcl-W inhibitor” CHEMBL408194 ↗ |
| Target | MCL1 | “Induced myeloid leukemia cell differentiation protein Mcl-1 inhibitor” CHEMBL408194 ↗ |